Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents
Official title: Precision Therapy for Solid Tumors: Synergistic Inhibition of Cell Proliferation and Angiogenesis Via CDK4/6 and Anti-VEGF Approach Targeting LncRNA Expression
Run by Lebanese University · NCT06307249 · Data updated 2026-11-12
This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Lebanese University Academic / other |
| Drugs / interventions | Bevacizumab, chemotherapy |
| Locations | 2 sites (Tripoli, North Lebanon and 1 other locations) |
| Status | Recruiting |
| Started | February 15, 2023 |
| Main results expected | December 2025 |
| Study ends | December 2027 |
| Registry record updated | March 12, 2024 |
| Trial ID | NCT06307249 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals over 18 years old with stage III or IV colorectal, breast, lung, or ovarian cancer.
✕Probably not a fit
Patients with a history of hematological cancers, autoimmune diseases, or other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the combined effects of Palbociclib, a CDK4/6 inhibitor, and Bevacizumab, an anti-VEGF agent, on patients with solid tumors, including colorectal, breast, and ovarian cancers. The study aims to explore the potential synergistic benefits of these therapies while also examining Long Non-Coding RNAs (LncRNAs) as biomarkers for treatment response. Patients will be stratified based on genetic risk factors, allowing for a precision medicine approach. The trial begins with colorectal cancer and plans to expand to other solid tumors, focusing on both efficacy and safety.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for patients with solid tumors.
How similar studies have gone: While the combination of CDK4/6 inhibitors and anti-VEGF agents is a novel approach, similar studies have shown promise in targeting solid tumors with dual therapies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals of white ethnicity. * Age between \> 18 * Both males and females. * Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer). * Cancer stage III/ IV with or without metastasis or lymph node dissemination at the time of enrollment. * Unrelated patients. Exclusion Criteria: * History of hematological cancer types or previous cancers, recurrent or relapse. * Diagnosis of inflammatory bowel diseases. * Pre-existing cardiovascular diseases or coronary artery diseases. * Confirmed treated or untreated autoimmune diseases. * Metabolic disorders, diabetes, or hypertension. * Neurological diseases. * Evidence of cardiac, renal, bone, or cerebral damage. * Presence of more than one type of malignancies. * Active infections or myositis. * Familial polyposis. * Alcohol or smoking habits. * Body mass index (BMI) \>30. * Significant weight loss within the last 2 years. * History of surgeries. * Pregnancy. * Related patients.
Where it's running
-
Haykel Hospital
Tripoli, North Lebanon, Lebanon Recruiting -
Lebanese University
Tripoli, North Lebanon, Lebanon Recruiting
Study contacts
- Study coordinator: Nehman Makdissy, Professor
- Email: nehman.makdissy@ul.edu.lb
- Phone: 71210250
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Riluzole to prevent thinking and memory problems during chemotherapy
This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.
-
IDOV-Immune for advanced solid tumors
This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.
-
Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues
This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.
-
Understanding the experiences of patients with chronic cancer treatments
This study is trying to understand how people with advanced chronic cancer feel about their targeted treatments by having them share their experiences through interviews and creative expressions like art and music.
-
A network for collaborative cancer research in Ontario
This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.
-
Validation of a blood test for early cancer detection and monitoring
This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.